Abemaciclib (Verzenio)

Key Messages

• CADTH recommends that Verzenio in combination with endocrine therapy should be reimbursed by public drug plans for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, nodepositive, early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score of at least 20% if certain conditions are met.
• Verzenio in combination with endocrine therapy should only be covered in patients whose breast cancer has receptors for the hormones estrogen and progesterone, tests negative for the HER2 protein, has been removed by surgery, and is at high risk of coming back based on certain risk features and the results of a biomarker test (i.e., Ki-67 test score ≥ 20%).
• Verzenio in combination with endocrine therapy should only be reimbursed if prescribed by clinicians with expertise in delivering systemic therapy and if the cost is reduced.